Sanofi to acquire Bioverativ for $11.6bn to expand into rare blood disorders
Sanofi has announced a definitive agreement to acquire Bioverativ, a US biotechnology company specializing in the treatment of hemophilia and other rare blood disorders, for approximately $11.6 billion. The all-cash transaction will involve Sanofi purchasing all outstanding shares of Bioverativ at $105 per share, marking a significant expansion of Sanofi’s presence in specialty care and […]